JenniferVenerisMDPhD

PubMed

• Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
  Ryan B Corcoran, Khanh T Do, Jeong E Kim, James M Cleary, Aparna R Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer Veneris, Leanne G Ahronian, Gianluca Ma...> ;Clinical Cancer Research. 2024 May 1
• 6 citations
  Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
  Thierry André, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier, Anna V Tinker, Ana Oaknin, Susan Ellard, Filippo de Braud, Hendrik-Tobias Arkenau, José Trigo, A...> ;JAMA Network Open. 2023 Nov 1
• A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
  Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O'Malley, Vanessa Samouelian, Valentina Boni, Linda Duska,...> ;Future Oncology. 2023 Aug 1
• 4 citations
  Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
  Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad Ghamande, Cara Mathews, David M O'Malley, Rebecca Kristeleit, Valentina Boni, Adriano...> ;Clinical Cancer Research. 2023 Nov 14
• 7 citations
  Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.
  Farzana Pashankar, Krisztina Hanley, Michelle Lockley, Sara Stoneham, Marisa R Nucci, Miguel Reyes-Múgica, Esther Elishaev, Russell Vang, Jennifer Veneris, Heather Ryt...> ;European Journal of Cancer. 2022 Sep 1
• 6 citations
  Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
  Victor Moreno, Desamparados Roda, Joanna Pikiel, Jose Trigo, Joaquim Bosch-Barrera, Yvette Drew, Rebecca Kristeleit, Sandrine Hiret, David L Bajor, Patricia Cruz, J Th...> ;Clinical Lung Cancer. 2022 Nov 1
• 119 citations
  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or profi...
  Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O'Malley, Vanessa Samouelian, Valentina Boni, Linda Duska,...> ;Journal for Immunotherapy of Cancer. 2022 Jan 1
• 71 citations
  Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
  Joyce F. Liu, Niya Xiong, Susana M. Campos, Alexi A. Wright, Carolyn N. Krasner, Susan Schumer, Neil S. Horowitz, Jennifer Taylor Veneris, Nabihah Tayob, Stephanie Mor...> ;Journal of Clinical Oncology. 2021 Mar 11
• 9 citations
  A serous borderline ovarian tumour in a transgender male adolescent.
  Kate Millington, Katherine Hayes, Sarah Pilcher, Stephanie A. Roberts, Sara O. Vargas, Amanda French, Jennifer Taylor Veneris, Allison F. O'Neill> ;British Journal of Cancer. 2021 Feb 2
• 21 citations
  Contemporary management of ovarian germ cell tumors and remaining controversies.
  Jennifer Taylor Veneris, Priya Mahajan, A. Lindsay Frazier> ;Gynecologic Oncology. 2020 Aug 1
• 42 citations
  Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
  Jennifer Taylor Veneris, Ursula A. Matulonis, Joyce F. Liu, Panagiotis A. Konstantinopoulos> ;Gynecologic Oncology. 2020 Feb 1
• 89 citations
  Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
  Joyce F. Liu, Michael S. Gordon, Jennifer Taylor Veneris, Fadi Braiteh, Ani Sarkis Balmanoukian, Joseph Paul Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sark...> ;Gynecologic Oncology. 2019 Aug 1
• 324 citations
  Current recommendations and recent progress in endometrial cancer.
  Rebecca A. Brooks, Gini F. Fleming, Ricardo R. Lastra, Nita K. Lee, John W. Moroney, Christina H. Son, Ken Tatebe, Jennifer L. Veneris> ;CA. 2019 Jul 1
• 17 citations
  Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
  Jennifer Taylor Veneris, Elizabeth K. Lee, Emily A. Goebel, Marisa R. Nucci, Neal I. Lindeman, Neil S. Horowitz, Larissa J. Lee, Chandrajit P. Raut, David Crotzer, Urs...> ;Gynecologic Oncology. 2019 Jun 1
• 14 citations
  Glucocorticoid Receptor Expression Is Associated With Inferior Overall Survival Independent of BRCA Mutation Status in Ovarian Cancer
  Jennifer Taylor Veneris, Lei Huang, Jane E. Churpek, Suzanne D. Conzen, Gini F. Fleming> ;International Journal of Gynecological Cancer. 2019 Feb 1
• 14 citations
  Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
  Ingvild L. Tangen, Jennifer Taylor Veneris, Mari K. Halle, Henrica M.J. Werner, Jone Trovik, Lars A. Akslen, Helga B. Salvesen, Suzanne D. Conzen, Gini F. Fleming, Cam...> ;Gynecologic Oncology. 2017 Dec 1
• 27 citations
  High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
  Jennifer Taylor Veneris, Kathleen M. Darcy, Paulette Mhawech-Fauceglia, Chunqiao Tian, Ernst Lengyel, Ricardo R. Lastra, Tanja Pejovic, Suzanne D. Conzen, Gini F. Fleming> ;Gynecologic Oncology. 2017 Jul 1
• 9 citations
  Using MKK4’s metastasis suppressor function to identify and dissect cancer cell–microenvironment interactions during metastatic colonization
  Venkatesh Krishnan, Nathan Stadick, Robert Clark, Russell Bainer, Jennifer Taylor Veneris, Shaheena Khan, Angela F. Drew, Carrie W. Rinker-Schaeffer> ;Cancer Metastasis Reviews. 2012 Jun 17
• 4 citations
  Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization
  Russell Bainer, Jennifer Taylor Veneris, S. Diane Yamada, Anthony G. Montag, Mark W. Lingen, Yoav Gilad, Carrie W. Rinker-Schaeffer> ;Clinical & Experimental Metastasis. 2012 Feb 21
• 11 citations
  MKK4 Suppresses Metastatic Colonization by Multiple Highly Metastatic Prostate Cancer Cell Lines Through a Transient Impairment in Cell Cycle Progression
  Russell Z. Szmulewitz, Robert Clark, Tamara L. Lotan, Kristen Otto, Jennifer Taylor Veneris, Kay F. Macleod, Carrie W. Rinker-Schaeffer> ;International Journal of Cancer. 2012 Feb 1
• 21 citations
  New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells
  Jennifer Taylor, Russell Z. Szmulewitz, Tamara L. Lotan, Jonathan A. Hickson, Donald J. Vander Griend, Seiko Diane Yamada, Kay F. Macleod, Carrie W. Rinker-Schaeffer> ;Cancer Letters. 2008 Dec 8
• 20 citations
  Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment
  Jennifer Taylor, Jonathan A. Hickson, Tamara L. Lotan, Diane Seiko Yamada, Carrie W. Rinker-Schaeffer> ;Cancer Metastasis Reviews. 2008 Mar 1
• Join now to see all

Lectures

• Selective and nonselective GR antagonists in combination with chemotherapy in ovarian cancer PDX models. 
  2019 ASCO Annual Meeting - 6/1/2019